IADR Abstract Archives
The Effect of a Natural-based Toothpaste (Parodontax®) on Plaque and Gingivitis: A Systematic Review
Objectives: The aim of the present study was to critically review the available published literature regarding the use of Parodontax® herbal toothpaste formulations and to determine whether there was supportive evidence for the safety and efficacy of Parodontax® toothpaste formulations for the reduction in plaque growth and on gingival inflammation.
Methods: A manual and electronic literature search (MEDLINE and Cochrane Central Register of Controlled Trials) was performed up to February 2015, for randomised controlled trials (RCT) presenting clinical, microbiological, immunological, and patient-centred data for the efficacy of Parodontax® in controlling both plaque and gingival inflammation.
Results: From 105 titles and abstracts, 98 were excluded and from the full text articles screened, seven randomized controlled trials were selected. Two of the included randomized controlled trials reported that Parodontax® toothpastes were similar in efficacy to the control dentifrices in effectively reducing both plaque and gingival inflammation in patients with gingivitis based on the assessment criteria of clinical, microbiological, and patient-centred treatment outcomes. Four of the included studies reported a significant effect of Parodontax® however there was a lack of clarity in the reporting of measures e.g., appropriate randomisation, calibration, blinding, and outcomes assessed (CONSORT), and therefore, the quality of both reporting and methodology may have been flawed with a high risk of bias.
Conclusions: The results from the published literature regarding the safety and clinical effectiveness of Parodontax® toothpaste would indicate that the toothpaste has some beneficial effects on plaque (to a lesser extent) and gingival inflammation. There are however limited data in terms of effectiveness for an anti-gingivitis agent over six months as recommended by the ADA. Furthermore some of the earlier studies were not based on the reporting guidelines from the CONSORT statement and as a consequence the evidence from these studies may not be as robust as currently recommended.
Methods: A manual and electronic literature search (MEDLINE and Cochrane Central Register of Controlled Trials) was performed up to February 2015, for randomised controlled trials (RCT) presenting clinical, microbiological, immunological, and patient-centred data for the efficacy of Parodontax® in controlling both plaque and gingival inflammation.
Results: From 105 titles and abstracts, 98 were excluded and from the full text articles screened, seven randomized controlled trials were selected. Two of the included randomized controlled trials reported that Parodontax® toothpastes were similar in efficacy to the control dentifrices in effectively reducing both plaque and gingival inflammation in patients with gingivitis based on the assessment criteria of clinical, microbiological, and patient-centred treatment outcomes. Four of the included studies reported a significant effect of Parodontax® however there was a lack of clarity in the reporting of measures e.g., appropriate randomisation, calibration, blinding, and outcomes assessed (CONSORT), and therefore, the quality of both reporting and methodology may have been flawed with a high risk of bias.
Conclusions: The results from the published literature regarding the safety and clinical effectiveness of Parodontax® toothpaste would indicate that the toothpaste has some beneficial effects on plaque (to a lesser extent) and gingival inflammation. There are however limited data in terms of effectiveness for an anti-gingivitis agent over six months as recommended by the ADA. Furthermore some of the earlier studies were not based on the reporting guidelines from the CONSORT statement and as a consequence the evidence from these studies may not be as robust as currently recommended.